XML 28 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Stock-Based Compensation | 9 Months Ended
--- | ---
Sep. 28, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (“ESPP”) as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Research and development | $ | 3,169 |  |  | $ | 1,663 |  |  | $ | 9,102 |  |  | $ | 4,741 |
Selling, general and administrative | 6,573 |  |  | 3,626 |  |  | 19,228 |  |  | 10,288 |
Total stock-based compensation | $ | 9,742 |  |  | $ | 5,289 |  |  | $ | 28,330 |  |  | $ | 15,029 |
We have several equity incentive plans under which we have granted stock options and restricted stock units (“RSUs”) to employees and directors. At September 30, 2018, 14,408,816 shares were available for grant under our equity incentive plans. We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Stock options | $ | 8.67 |  |  | $ | 11.75 |  |  | $ | 9.13 |  |  | $ | 10.32 |
ESPP | $ | 6.19 |  |  | $ | 6.85 |  |  | $ | 6.96 |  |  | $ | 5.29 |
The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Stock options: |  |  |  |  |  |  |
Risk-free interest rate | 2.91 | % |  | 1.70 | % |  | 2.83 | % |  | 1.68 | %
Dividend yield | — | % |  | — | % |  | — | % |  | — | %
Volatility | 55 | % |  | 58 | % |  | 55 | % |  | 61 | %
Expected life | 4.4 years |  |  | 4.0 years |  |  | 4.4 years |  |  | 4.1 years |
ESPP: |  |  |  |  |  |  |
Risk-free interest rate | 2.11 | % |  | 1.14 | % |  | 1.74 | % |  | 0.88 | %
Dividend yield | — | % |  | — | % |  | — | % |  | — | %
Volatility | 51 | % |  | 55 | % |  | 52 | % |  | 61 | %
Expected life | 6 months |  |  | 6 months |  |  | 6 months |  |  | 6 months |
We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. Activity for stock options during the nine months ended September 30, 2018 was as follows (dollars in thousands, except per share amounts):
| Shares |  | Weighted Average Exercise Price Per Share |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
Options outstanding at December 31, 2017 | 22,208,446 |  |  | $ | 6.83 |  |  |  |  |
Granted | 3,022,113 |  |  | $ | 19.52 |  |  |  |  |
Exercised | (2,083,457 | ) |  | $ | 5.01 |  |  |  |  |
Forfeited | (216,522 | ) |  | $ | 14.40 |  |  |  |  |
Expired | (5,548 | ) |  | $ | 18.62 |  |  |  |  |
Options outstanding at September 30, 2018 | 22,925,032 |  |  | $ | 8.59 |  |  | 3.9 years |  | $ | 226,821 |
Exercisable at September 30, 2018 | 15,896,370 |  |  | $ | 5.03 |  |  | 3.1 years |  | $ | 203,118 |
In September 2018, in connection with our long-term incentive compensation program, we granted 308,365 stock options t o our President and Chief Executive Officer that have a market vesting condition (“PSOs”). In addition to the standard service conditions included in our other stock options, these PSOs may not be exercised unless, at any time after the grant date, the fair market value of a share of our Common Stock is at least 125% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. As of September 30, 2018, there was $52.8 million of unrecognized compensation expense related to our unvested stock options that will be recognized over a weighted-average period of 2.6 years. Activity for RSUs during the nine months ended September 30, 2018 was as follows (dollars in thousands, except per share amounts):
| Shares |  | Weighted Average Grant Date Fair Value Per Share |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
RSUs outstanding at December 31, 2017 | 3,762,990 |  |  | $ | 17.76 |  |  |  |  |
Awarded | 2,411,245 |  |  | $ | 18.50 |  |  |  |  |
Vested and released | (374,992 | ) |  | $ | 8.18 |  |  |  |  |
Forfeited | (249,362 | ) |  | $ | 18.64 |  |  |  |  |
RSUs outstanding at September 30, 2018 | 5,549,881 |  |  | $ | 18.69 |  |  | 2.1 years |  | $ | 98,344 |
In September 2018, in connection with our long-term incentive compensation program, we awarded 693,131 RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (“PSUs”). The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is probable. We have not recognized any compensation expense related to these PSUs. As of September 30, 2018, the total unrecognized compensation expense related to the unvested PSUs was $12.7 million. As of September 30, 2018, there was $87.6 million of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The RSUs will be recognized over a weighted-average period of 3.2 years.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration